Recent developments highlight leadership changes, strategic transactions, and operational updates that reflect Evotec's evolving business model and market positioning.

• Evotec nominated Dieter Weinand as Supervisory Board Chairman in April 2026 [N1].
• The company completed the sale of its Just-Evotec Biologics EU SAS Toulouse site to Sandoz AG in December 2025, advancing its asset-light strategy with an upfront payment of USD 350 million and potential future milestone and royalty revenues [N2][N4].
• Evotec adjusted its FY25 revenue guidance while maintaining its adjusted EBITDA outlook in July 2025 [N5].
• The company reported a widened net loss in Q1 2025 but confirmed revenue guidance for FY25 and FY28 [N6].
• Evotec's annual revenue rose in 2025, with the company providing an outlook for FY25 [N7].
• The Chief Operating Officer announced stepping down effective December 31, 2024 [N8].
• Halozyme withdrew its acquisition proposal for Evotec in November 2024, reaffirming Evotec's standalone strategy [N8].

Evotec's strategic shift to an asset-light model, exemplified by the sale of its biologics manufacturing site to Sandoz, improves liquidity and reduces capital expenditure burdens, allowing greater focus on core R&D platforms and AI-driven innovation. The company's integrated platform across multiple modalities and disease areas, combined with its proprietary technologies and extensive scientific expertise, positions it well to meet evolving industry demands for precision medicine and external innovation. Its broad and growing customer base, including major pharmaceutical partners, supports revenue diversification. The increasing share of revenues from milestone payments and potential royalties from partnered assets offers upside in profitability. Operational streamlining and the establishment of Centers of Excellence aim to enhance efficiency and cost management.

Evotec faces risks from the challenging macroeconomic environment impacting biotech funding and early-stage drug discovery markets, which may constrain demand for its services. The company's financial results depend partly on the success and decisions of its partners in clinical development, over which Evotec has limited control. The concentration of revenues among a few large customers could pose risks if partnerships change. Transitioning to an asset-light model involves execution risks, including maintaining service quality and access to manufacturing capacity through partnerships. Continued net losses and the need for operational improvements highlight ongoing financial and execution challenges. Regulatory and competitive pressures in the drug discovery and biologics manufacturing sectors also present risks.

Evotec's competitive moat is built on its fully integrated drug discovery and development platform that spans the entire R&D value chain, combining proprietary technologies such as molecular patient databases, induced pluripotent stem cell disease modeling, and AI-driven innovation. This comprehensive, modality-agnostic platform differentiates Evotec from competitors who typically offer more limited, discrete services. The company's deep scientific expertise, with a large workforce of highly qualified scientists, and its broad disease area coverage further strengthen its position. Additionally, Evotec's strategic partnerships with leading pharmaceutical and biotechnology companies, along with its co-development pipeline and potential milestone and royalty revenues, provide diversified revenue streams and reduce risk. The recent transition to an asset-light business model through the sale of biologics manufacturing assets enhances financial flexibility and focuses resources on high-value R&D activities, reinforcing its competitive advantages.

• Dependence on Partner Success and Decisions: Evotec's financial performance is partly dependent on the clinical development success and strategic decisions of its partners, which it cannot control, potentially impacting milestone and royalty revenues.
• Customer Concentration: A significant portion of revenues is concentrated among a few large customers, including Bristol Myers Squibb and Sandoz, which could affect revenue stability if these relationships change.
• Market and Funding Environment: The early-stage drug discovery market faces challenges due to low biotech funding and macroeconomic pressures, which may reduce demand for Evotec's services.
• Execution Risks in Asset-Light Transition: The shift to an asset-light business model requires effective execution to maintain service quality and manufacturing capacity through partnerships, with risks of operational disruption.
• Ongoing Net Losses and Financial Performance: Evotec has reported net losses, reflecting ongoing challenges in achieving profitability despite revenue growth and operational improvements.

• Evotec SE is a European stock corporation (Societas Europaea) incorporated in Germany, with principal executive offices in Hamburg, Germany [S1].
• The company operates as an integrated drug discovery, preclinical development, and manufacturing innovation hub, providing services and platforms to pharmaceutical and biotechnology partners [S1].
• Evotec's workforce included 3,682 scientific experts as of December 31, 2025, covering a broad range of disease areas including oncology, CNS disorders, cardiovascular-renal disorders, immune & inflammatory diseases, infectious diseases, fibrotic and respiratory diseases, women's health, rare diseases, and animal health [S1].
• The company focuses on technology and science leadership, emphasizing AI-driven innovation, molecular glue degraders, and targeted protein degradation [S1].
• Evotec's proprietary platforms include molecular patient databases, induced pluripotent stem-cell based disease modeling, high-performance Omics technologies, and integrated platforms for drug screening, profiling, development, and manufacturing [S1].
• Evotec's business model includes fee-for-service and full-time equivalent (FTE) rate-based contracts, milestone payments, royalties, and equity ownership in biotechnology companies and academic projects [S1].
• In 2025, approximately 79% of revenues were from fee-for-service or FTE-based arrangements, with milestone payments contributing 1.2% of total revenues; royalties were not significant at this stage [S1].
• Evotec operates two main segments: Discovery & Preclinical Development (D&PD) and Just – Evotec Biologics (JEB) [S1].
• The D&PD segment focuses on drug discovery and preclinical development services, emphasizing high-growth, high-value segments and operational excellence [S1].
• The JEB segment provides biologics discovery, optimization, development, and manufacturing services, including antibody discovery, molecular optimization, process and product design, cell line and media development, and continuous biomanufacturing under GMP [S1].
• In December 2025, Evotec sold its JEB Toulouse site to Sandoz AG, marking a strategic shift to an asset-light business model with upfront cash payment of USD 350 million and potential future revenues from technology licenses, milestones, and royalties [S1][N2][N4].
• JEB accounted for 33% of revenues from third parties in the twelve months ended December 31, 2025, up from 23% in 2024 and 14% in 2023 [S1][N4].
• D&PD accounted for 67% of revenues from third parties in 2025, down from 77% in 2024 and 86% in 2023 [S1].
• Evotec's platform is modality-agnostic, covering small molecules, biologics, RNA-targeting approaches, and cell therapy [S1].
• The company emphasizes precision medicine through integration of molecular patient databases, PanOmics platforms, and iPSC-based drug screening [S1].
• Evotec's customer base included 735 customers in 2025, with 225 new customers added that year; the top ten customers contributed 61% of total revenues, with Bristol Myers Squibb and Sandoz each accounting for more than 10% [S1].
• Evotec reported revenues of EUR 796.97 million for the year ended December 31, 2024, with a net loss of EUR 196.08 million and basic and diluted EPS of -1.11 EUR/share [S1].
• Liquidity ratios as of December 31, 2024, included a current ratio of 1.98 and a cash ratio of 0.89, with cash and equivalents of EUR 306.39 million and current assets of EUR 681.96 million against current liabilities of EUR 344.59 million [S1].
• The company has been focusing on operational excellence, complexity reduction, and streamlining its global footprint, including closing the Cologne site in early 2025 and planning to reduce to 10 sites with Centers of Excellence [S1].
• Evotec's adjusted EBITDA increased to EUR 41.1 million in 2025 from EUR 22.6 million in 2024, reflecting improved operating performance [S1].
• Recent leadership changes include the nomination of Dieter Weinand as Supervisory Board Chairman in April 2026 [N1].
• The company announced the departure of its Chief Operating Officer effective December 31, 2024 [N8].
• Evotec's asset-light strategy accelerated with the biosimilars deal to Sandoz valued at USD 300 million [N4].
• Halozyme withdrew its acquisition proposal for Evotec in November 2024, reaffirming Evotec's standalone strategy [N8].